COVID-19 remdesivir study finds long hospital stay, but context matters

Remdesivir, the only antiviral fully approved for COVID-19 treatment by the US Food and Drug Administration (FDA), was associated with a longer hospital stay yet no improvement in survival rates, according to a real-world observational study of military veterans today in JAMA Network Open. The researchers suggest that the prescribed regimen (5 or 10 days) may have led to longer hospitalizations as patients finished the treatment course, and a related commentary agrees.